BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 32866816)

  • 1. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
    Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
    J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
    Jin L; Kiang KM; Cheng SY; Leung GK
    Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
    Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
    Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
    Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
    Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Hegi ME; Genbrugge E; Gorlia T; Stupp R; Gilbert MR; Chinot OL; Nabors LB; Jones G; Van Criekinge W; Straub J; Weller M
    Clin Cancer Res; 2019 Mar; 25(6):1809-1816. PubMed ID: 30514777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
    Struve N; Binder ZA; Stead LF; Brend T; Bagley SJ; Faulkner C; Ott L; Müller-Goebel J; Weik AS; Hoffer K; Krug L; Rieckmann T; Bußmann L; Henze M; Morrissette JJD; Kurian KM; Schüller U; Petersen C; Rothkamm K; O Rourke DM; Short SC; Kriegs M
    Oncogene; 2020 Apr; 39(15):3041-3055. PubMed ID: 32066879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
    Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
    J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
    Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
    Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
    J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
    Wu Q; Berglund AE; Macaulay RJ; Etame AB
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
    Gan T; Wang Y; Xie M; Wang Q; Zhao S; Wang P; Shi Q; Qian X; Miao F; Shen Z; Nie E
    Cancer Res; 2022 Nov; 82(22):4234-4246. PubMed ID: 36112059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
    Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M
    Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells.
    Tsuji S; Nakamura S; Shoda K; Yamada T; Shimazawa M; Nakayama N; Iwama T; Hara H
    J Neurooncol; 2022 Nov; 160(2):375-388. PubMed ID: 36308592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
    Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
    Ganesa S; Sule A; Sundaram RK; Bindra RS
    Sci Rep; 2022 Apr; 12(1):5827. PubMed ID: 35388070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation.
    Wu M; Song D; Li H; Ahmad N; Xu H; Yang X; Wang Q; Cheng X; Deng S; Shu X
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.
    Xin L; Tan Y; Zhu Y; Cui X; Wang Q; Zhao J; Tian S; Xu C; Xiao M; Hong B; Xu J; Yuan X; Wang C; Kang C; Fang C
    Neuro Oncol; 2023 Nov; 25(11):1976-1988. PubMed ID: 37279651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status.
    Vázquez-Blomquist D; Leenstra S; van der Kaaij M; Villarreal A; Bello-Rivero I
    Mol Biol Rep; 2020 Jul; 47(7):5263-5271. PubMed ID: 32607953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.